#United States #New York #Pomerantz LLP #Skye Bioscience #SKYE

Investor Alert: Pomerantz Law Firm Investigates Skye Bioscience, Inc.

Pomerantz LLP is currently conducting an investigation into allegations of potential securities fraud related to Skye Bioscience, Inc. (NASDAQ: SKYE). This inquiry seeks to determine whether there have been any unlawful business practices involved in the company's operations. Investors are particularly interested in the legal implications regarding certain actions taken by Skye's leadership, which may have contributed to significant fluctuations in the stock's performance.

On October 6, 2025, Skye published a press release that revealed the topline results from its 26-week Phase 2a CBeyond™ study. The findings showed that the specific arm of the study utilizing nimacimab—an experimental drug intended to act as a peripherally-restricted CB1 inhibitor antibody—did not meet its primary objective of promoting weight loss when compared to a placebo. Additionally, preliminary analyses indicated lower-than-expected drug exposure, suggesting that higher dosing may be required for effective results.

In light of these disclosures, Skye's stock suffered a notable decrease, plummeting by $2.85 per share, equivalent to a 60% decline, closing at $1.90 on the same day. Such a drastic shift in the stock price is driving investor concerns, prompting the need for an investigation to assess the validity of the concerns raised and to establish whether the company had sufficiently informed shareholders about the risks involved.

Pomerantz LLP, renowned for its dedication to defending the rights of investors and its long-standing reputation in corporate and securities class actions, encourages affected investors to reach out for more information on the investigation. The firm has a history of successfully advocating for justice in matters of securities fraud, safeguarding the interests of those who may have been misled.

For inquiries, investors are advised to connect with Danielle Peyton at Pomerantz LLP via email or phone at the information provided in the press release. The investigation aims to unfold any misconduct or misleading actions committed by the company or its leaders, potentially impacting investor confidence and the integrity of the securities market.

As the situation develops, it remains essential for investors to keep a close watch on the evolving narrative surrounding Skye Bioscience. The results from the Phase 2a study are crucial not only for the company's future but also for its shareholders who have incurred losses due to the unexpected turn of events. The investigation by Pomerantz LLP may lead to further actions to hold the responsible parties accountable, ensuring that investor rights are preserved. It is advisable for investors to stay informed and participate in any class action initiatives that may arise from this investigation as they work toward recouping their investments in light of the situation.